Functional ovarian reserve in women with Hodgkin and non-Hodgkin lymphomas

Abstract

Introduction: Hematological malignancies may impair ovarian function even before chemotherapy begins, raising concerns about the effectiveness of oocyte cryopreservation. However, available evidence remains conflicting, partly because of confounding factors and suboptimal study designs. This study investigated whether women with lymphoma show reduced ovarian reserve or impaired ovarian response compared with women without cancer and women with non-hematologic malignancies.

Methods: We conducted a retrospective analysis of women with Hodgkin and non-Hodgkin lymphomas who underwent oocyte cryopreservation for fertility preservation at our Institution. Each patient was age- and study period-matched to two control groups: one comprising women without cancer undergoing Assisted Reproductive Technologies for infertility, allowing comparison of ovarian reserve markers (Anti-Müllerian Hormone, AMH, and antral follicle count, AFC), and another comprising women with non-hematologic solid tumors to compare ovarian stimulation outcomes.

Results: The first comparison included 66 cases and 66 controls without cancer. Median [interquartile range – IQR] serum AMH was 1.97 [1.14-3.23] and 2.94 [2.12-4.60], respectively (p=0.002). However, AFC was similar (18 [12-24] versus 15 [11-21], p=0.16). The second comparison involved 74 cases and 74 non-hematologic cancer controls. Ovarian response was similar between groups, with a median [IQR] number of frozen mature oocytes of 10 [6–15] and 13 [6–16], respectively (p=0.56).

Conclusion: Early alterations in follicular function may occur in women with lymphoma. Nevertheless, ovarian response to stimulation appears preserved, supporting the effectiveness of fertility preservation.

Pretreatment AMH–AFC stratification of poor-ovarian-response risk in young women with diminished ovarian reserve: a multicentre retrospective cohort study
Yanning Lv, Jiahao Fang, Haiyan Yang +3
Frontiers in endocrinology16 Oct 2026Peer-reviewedCC BYFull textEndocrinology & metabolismEurope PMC
Preserved ovarian reserve in night-active versus day-active women: a cross-sectional comparison of neuroendocrine markers.
Ezgi Gungor, Kubra Sevim Pehlivan, Aysegul Ciydem +1
BMC women's health2 Sep 2026Peer-reviewedCC BY-NC-NDFull textObstetrics, gynaecology & paediatricsEurope PMCPMC
Impact of unilateral salpingectomy on ovarian reserve and long-term reproductive outcomes in reproductive-aged women
Yanna Zhou, Yiting Yang
Frontiers in Endocrinology12 Oct 2026Peer-reviewedCC BY 4.0Full textEpidemiology & public healthPMCCrossrefEurope PMC
Association of vitamin E and coenzyme Q10 pretreatment with embryological and pregnancy outcomes in women with diminished ovarian reserve: a retrospective study
Shiyu Wang, Tianjuan Wang, Wenxiang Zhang +2
Frontiers in Endocrinology21 Oct 2026Peer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossrefPMC
Impact of vasopressin-assisted laparoscopic endometrioma excision on ovarian reserve: a randomized controlled trial
Jaehoon Lee, Eunhyang Park, Hyemin Park +4
Frontiers in reproductive health19 Oct 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeX RIS

BibTeX

@article{filippi2026functional,
  title = {{Functional ovarian reserve in women with Hodgkin and non-Hodgkin lymphomas}},
  author = {Francesca Filippi and Nicole Serra and Sabrina Comana and Giorgia Di Stefano and Marco Reschini and Paola Vigano’ and Edgardo Somigliana},
  journal = {Frontiers in oncology},
  year = {2026},
  month = oct,
  doi = {10.3389/fonc.2026.1965843},
  url = {https://europepmc.org/article/PMC/PMC13690508},
  note = {CC BY},
}

RIS

TY  - JOUR
TI  - Functional ovarian reserve in women with Hodgkin and non-Hodgkin lymphomas
AU  - Francesca Filippi
AU  - Nicole Serra
AU  - Sabrina Comana
AU  - Giorgia Di Stefano
AU  - Marco Reschini
AU  - Paola Vigano’
AU  - Edgardo Somigliana
PY  - 2026
DA  - 2026/10/09
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2026.1965843
UR  - https://europepmc.org/article/PMC/PMC13690508
AB  - Introduction: Hematological malignancies may impair ovarian function even before chemotherapy begins, raising concerns about the effectiveness of oocyte cryopreservation. However, available evidence remains conflicting, partly because of confounding factors and suboptimal study designs. This study investigated whether women with lymphoma show reduced ovarian reserve or impaired ovarian response compared with women without cancer and women with non-hematologic malignancies.  Methods: We conducted a retrospective analysis of women with Hodgkin and non-Hodgkin lymphomas who underwent oocyte cryopreservation for fertility preservation at our Institution. Each patient was age- and study period-matched to two control groups: one comprising women without cancer undergoing Assisted Reproductive Technologies for infertility, allowing comparison of ovarian reserve markers (Anti-Müllerian Hormone, AMH, and antral follicle count, AFC), and another comprising women with non-hematologic solid tumors to compare ovarian stimulation outcomes.  Results: The first comparison included 66 cases and 66 controls without cancer. Median [interquartile range – IQR] serum AMH was 1.97 [1.14-3.23] and 2.94 [2.12-4.60], respectively (p=0.002). However, AFC was similar (18 [12-24] versus 15 [11-21], p=0.16). The second comparison involved 74 cases and 74 non-hematologic cancer controls. Ovarian response was similar between groups, with a median [IQR] number of frozen mature oocytes of 10 [6–15] and 13 [6–16], respectively (p=0.56).  Conclusion: Early alterations in follicular function may occur in women with lymphoma. Nevertheless, ovarian response to stimulation appears preserved, supporting the effectiveness of fertility preservation.
SN  - 2234-943X
ER  -

Abstract

Related

Cite